In summary, we observed specific augmentation of anti-inflammatory DAM as well as overall augmentation of Aβ phagocytosis by an agonist of LXRα/β, consistent with our network-based predictions and with known Aβ-lowering effects of LXRα/β agonists in AD models [42]. This evidence concerns the gene NR1H3 and Alzheimer disease.